News archive
icon
Showing 739 results
November 2025
-
Story

Community Health Solutions: How We’re Meeting People Where They Are to Improve Community Health
Learn how community-driven partnerships are helping to break down barriers and support access to health care.
-
Story Education and Awareness

Five questions with Eden Wells, Chief Insights and Decision Science Officer at Novartis US
In this interview, Eden discusses the pivotal moments that shaped her career, her passion for advancing patient care and her vision for a future where timely and accessible healthcare is a reality for everyone.
-
Story

How This Former Army Officer Helps Deliver Cancer Treatments to Patients, Through Hurricanes and Beyond
Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.
-
Media Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of… -
Story Education and Awareness

Changing Lives: Inside the Novartis Corporate Teen Mentoring Program
At this award-winning two-day event, more than 150 high school students gathered to acquire professional skills that will empower them to lead successful futures.
-
Media Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio C3…
October 2025
-
Media Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across… -
Media Release
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell… -
Story Hope

Underserved but Not Out of Reach: 3 Ways to Bridge Care Gaps in Communities to Improve Advanced Prostate Cancer
Creating truly equal care for patients with advanced prostate cancer begins by learning from those often overlooked and help them feel seen, heard, and understood.
-
Media Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo… -
Story Education and Awareness

Five Questions with Katie Mazuk, Novartis US Chief Patient Experience Officer
In this interview, Katie shares the experiences that have shaped her leadership philosophy, her vision for pioneering new approaches in patient support, and why she believes the future of healthcare lies in combining technological innovation with genuine connection.
-
Media Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 62
- › Next page